Search Results

You are looking at 101 - 110 of 785 items for :

  • "risk factor" x
  • Refine by Access: All x
Clear All
Full access

Himani Aggarwal, Li Li, Gebra Cuyun Carter, Kathy Fraeman, and Ariel Berger

risk factors included alcohol use, diabetes, and distant metastases. Conclusions: HPV-positive status was associated with a decreased risk of mortality among OPC patients in this study. Despite the small sample size and potential violation of

Full access

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, and Eunice S. Wang

. The panel has focused on outlining reasonable treatment options based on recent clinical trials and data from basic science, which may identify new risk factors and treatment approaches. In some areas, panel members have divergent opinions about the

Full access

Chunkit Fung, Sophie D. Fossa, Clair J. Beard, and Lois B. Travis

known cancer risk factors, 31 such as smoking. 11 Chamie et al. 30 conducted a retrospective study to determine if patients with stage I nonseminoma who forewent RPLND had higher risks of SMN than those who underwent RPLND, with the assumption that

Full access

Emma Gargus, Rebecca Deans, Antoinette Anazodo, and Teresa K. Woodruff

, 19 , 24 , 30 , 33 , 37 , 41 Prevalence of and Risk Factors for POI in Survivors Depending on patient factors, cancer diagnosis, and treatment exposures, the prevalence of POI in survivors of pediatric and AYA cancer ranged from 2.1% to 82

Full access

Michaela A. Dinan, Bradford R. Hirsch, and Gary H. Lyman

associated with an intermediate risk of FN in the range of 10% to 20%. For patients receiving myelosuppressive chemotherapy regimens with an intermediate risk of FN, guidelines recommend assessing patient-specific risk factors. Although many such factors have

Full access

Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma, and Imran Zoberi

applied to obtain the final multivariable model. In patients who did not experience pCR, the Kaplan-Meier method was used to estimate whether those with multiple risk factors had an increased risk of LRR compared with those with a single risk factor

Full access

William R. Kennedy, Christopher Tricarico, Prashant Gabani, Ashley A. Weiner, Michael B. Altman, Laura L. Ochoa, Maria A. Thomas, Julie A. Margenthaler, Souzan Sanati, Lindsay L. Peterson, Cynthia X. Ma, Foluso O. Ademuyiwa, and Imran Zoberi

-based NAC do not experience pCR, 8 , 9 and data are scarce regarding clinically identifiable prognostic risk factors in this cohort of patients who have residual disease after NAC. We recently identified risk factors for locoregional recurrence (LRR) in

Full access

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Breast cancer is the most commonly diagnosed cancer in American women, with an estimated 214,640 cases and 41,430 deaths occurring in 2006. Estimating breast cancer risk for individual women is difficult, and most breast cancers are not attributable to risk factors other than female gender and increased age. Developing effective strategies for reducing breast cancer incidence is also difficult because few existing risk factors are modifiable and some potentially modifiable risk factors have social implications. Nevertheless, effective breast cancer risk reduction agents and strategies, such as tamoxifen, raloxifene, and risk reduction surgery, have been identified. These guidelines were developed to help women at increased risk for breast cancer and their physicians apply individualized strategies to reduce breast cancer risk.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Stefanie L. Thorsness, Azael Freites-Martinez, Michael A. Marchetti, Cristian Navarrete-Dechent, Mario E. Lacouture, and Emily S. Tonorezos

– 7 Although rarely a metastatic tumor, 8 NMSC can cause significant disfigurement and local destruction. Radiotherapy (RT) is a well-known risk factor for NMSC. 9 – 11 Retrospective studies have associated use of RT in the treatment of tinea

Full access

Benjamin E. Greer, Wui-Jin Koh, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Warner K. Huh, Daniel S. Kapp, John R. Lurain III, Lainie Martin, Mark A. Morgan, Robert J. Morgan Jr., David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr., Nelson Teng, and Fidel A. Valea

Clinical Practice Guidelines in Oncology [NCCN Guidelines] for Cervical Cancer Screening, in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org ). 8 – 12 Other epidemiologic risk factors associated